Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Latigo Biotherapeutics, Inc. (LTGO) is the issuer of common stock for which AI Biotechnology LLC, Access Industries Holdings LLC, Access Industries Management, LLC, and Len Blavatnik report shared voting and dispositive power over 3,193,565 shares, equal to 4.8% of the class.
AI Biotechnology holds the shares directly; the other reporting persons may also be deemed beneficial owners through the stated control relationships, while each of them disclaims beneficial ownership. The reported percentage is based on 66,299,347 shares outstanding as of November 2, 2026.
Key Figures
Shares held directly by AI Biotechnology:3,193,565 sharesReported ownership percentage:4.8%Common shares outstanding:66,299,347 shares
3 metrics
Shares held directly by AI Biotechnology3,193,565 sharesReported shared voting and dispositive power
Reported ownership percentage4.8%Based on shares outstanding as of November 2, 2026
Common shares outstanding66,299,347 sharesAs of November 2, 2026
Key Terms
beneficial ownership, shared voting power, shared dispositive power
3 terms
beneficial ownershipfinancial
"Amount beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting powerfinancial
"Shared Voting Power 3,193,565"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"Shared Dispositive Power 3,193,565"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many LTGO shares does AI Biotechnology report?
AI Biotechnology holds 3,193,565 shares directly. The same position may also be deemed beneficially owned by Access Industries Holdings LLC, Access Industries Management, LLC, and Len Blavatnik through the stated control relationships.
What percentage of LTGO does the reported position represent?
The reported position represents 4.8% of the common stock, calculated using 66,299,347 shares outstanding as of November 2, 2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Latigo Biotherapeutics, Inc.
(Name of Issuer)
Common stock, par value $0.0001 per share
(Title of Class of Securities)
517954103
(CUSIP Number)
09/03/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
517954103
1
Names of Reporting Persons
AI Biotechnology LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,193,565.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,193,565.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,193,565.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.8 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The percentage reported herein is calculated based upon 66,299,347 shares of Common Stock outstanding as of November 2, 2026, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 5, 2026.
SCHEDULE 13G
CUSIP Number(s):
517954103
1
Names of Reporting Persons
Access Industries Holdings LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,193,565.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,193,565.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,193,565.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.8 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The percentage reported herein is calculated based upon 66,299,347 shares of Common Stock outstanding as of November 2, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on November 5, 2026.
SCHEDULE 13G
CUSIP Number(s):
517954103
1
Names of Reporting Persons
Access Industries Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,193,565.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,193,565.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,193,565.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.8 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The percentage reported herein is calculated based upon 66,299,347 shares of Common Stock outstanding as of November 2, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on November 5, 2026.
SCHEDULE 13G
CUSIP Number(s):
517954103
1
Names of Reporting Persons
Len Blavatnik
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,193,565.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,193,565.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,193,565.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.8 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: (1) The percentage reported herein is calculated based upon 66,299,347 shares of Common Stock outstanding as of November 2, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on November 5, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Latigo Biotherapeutics, Inc.
(b)
Address of issuer's principal executive offices:
1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, CA 91320
Item 2.
(a)
Name of person filing:
AI Biotechnology LLC
Access Industries Holdings LLC ("AIH")
Access Industries Management, LLC ("AIM")
Len Blavatnik
(b)
Address or principal business office or, if none, residence:
The principal business office of each reporting person is c/o Access Industries, Inc., 40 West 57th Street, 28th Floor, New York, NY 10019.
(c)
Citizenship:
Each of AI Biotechnology, AIH and AIM is a limited liability company organized under the laws of the State of Delaware.
Mr. Blavatnik is a citizen of the United States of America.
(d)
Title of class of securities:
Common stock, par value $0.0001 per share
(e)
CUSIP No.:
517954103
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See the responses to Item 9 on the attached cover pages.
(b)
Percent of class:
See the responses to Item 11 on the attached cover pages. The percentages reported in Item 11 on the attached cover pages are based upon 66,299,347 shares of Common Stock outstanding as of November 2, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on November 5, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See the responses to Item 5 on the attached cover pages.
(ii) Shared power to vote or to direct the vote:
See the responses to Item 6 on the attached cover pages.
(iii) Sole power to dispose or to direct the disposition of:
See the responses to Item 7 on the attached cover pages.
(iv) Shared power to dispose or to direct the disposition of:
See the responses to Item 8 on the attached cover pages.
3,193,565 shares of Common Stock are held directly by AI Biotechnology and may also be deemed to be beneficially owned by AIH, AIM and Mr. Blavatnik because (i) Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH, (ii) AIM controls AIH, and (iii) AIH controls all of the outstanding voting interests in AI Biotechnology. Each of the Reporting Persons (other than AI Biotechnology) and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
AI Biotechnology LLC
Signature:
/s/ Alejandro Moreno
Name/Title:
By: Access Industries Management, LLC, its manager; its Executive Vice President/Alejandro Moreno
Date:
11/06/2026
Access Industries Holdings LLC
Signature:
/s/ Alejandro Moreno
Name/Title:
By: Access Industries Management, LLC, its manager; its Executive Vice President/Alejandro Moreno
Date:
11/06/2026
Access Industries Management, LLC
Signature:
/s/ Alejandro Moreno
Name/Title:
Executive Vice President/Alejandro Moreno
Date:
11/06/2026
Len Blavatnik
Signature:
*/s/Alejandro Moreno
Name/Title:
By: Alejandro Moreno/Attorney-in-Fact
Date:
11/06/2026
Comments accompanying signature: * The undersigned, by signing his name hereto, executes this Amendment No. 1 to Schedule 13G pursuant to the Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.
